These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 16954794)
21. Efficacy and response with olopatadine versus epinastine in ocular allergic symptoms: a post hoc analysis of data from a conjunctival allergen challenge study. Finegold I; Granet DB; D'Arienzo PA; Epstein AB Clin Ther; 2006 Oct; 28(10):1630-8. PubMed ID: 17157118 [TBL] [Abstract][Full Text] [Related]
22. The anti-inflammatory effects of therapies for ocular allergy. Mantelli F; Calder VL; Bonini S J Ocul Pharmacol Ther; 2013 Nov; 29(9):786-93. PubMed ID: 24044620 [TBL] [Abstract][Full Text] [Related]
23. Intranasal corticosteroids reduce ocular symptoms associated with allergic rhinitis. Naclerio R Otolaryngol Head Neck Surg; 2008 Feb; 138(2):129-39. PubMed ID: 18241703 [TBL] [Abstract][Full Text] [Related]
24. Future directions in therapeutic interventions for conjunctival inflammatory disorders. Pflugfelder SC; Stern ME Curr Opin Allergy Clin Immunol; 2007 Oct; 7(5):450-3. PubMed ID: 17873588 [TBL] [Abstract][Full Text] [Related]
25. The central role of conjunctival mast cells in the pathogenesis of ocular allergy. Leonardi A Curr Allergy Asthma Rep; 2002 Jul; 2(4):325-31. PubMed ID: 12044269 [TBL] [Abstract][Full Text] [Related]
34. Conjunctival provocation test as a model for the study of allergy and inflammation in humans. Bonini S; Bonini S; Berruto A; Tomassini M; Carlesimo S; Bucci MG; Balsano F Int Arch Allergy Appl Immunol; 1989; 88(1-2):144-8. PubMed ID: 2651314 [TBL] [Abstract][Full Text] [Related]
35. Epinastine: topical ophthalmic second generation antihistamine without significant systemic side effects. Pradhan S; Abhishek K; Mah F Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1135-40. PubMed ID: 19630694 [TBL] [Abstract][Full Text] [Related]
36. Hyperosmolar conjunctival provocation for the evaluation of nonspecific hyperreactivity in healthy patients and patients with allergy. Sacchetti M; Lambiase A; Aronni S; Griggi T; Ribatti V; Bonini S; Bonini S J Allergy Clin Immunol; 2006 Oct; 118(4):872-7. PubMed ID: 17030240 [TBL] [Abstract][Full Text] [Related]
37. Clinical implications of mast cell involvement in allergic conjunctivitis. Elieh Ali Komi D; Rambasek T; Bielory L Allergy; 2018 Mar; 73(3):528-539. PubMed ID: 29105783 [TBL] [Abstract][Full Text] [Related]
38. Blocking mast cell-mediated type I hypersensitivity in experimental allergic conjunctivitis by monocyte chemoattractant protein-1/CCR2. Tominaga T; Miyazaki D; Sasaki S; Mihara S; Komatsu N; Yakura K; Inoue Y Invest Ophthalmol Vis Sci; 2009 Nov; 50(11):5181-8. PubMed ID: 19553621 [TBL] [Abstract][Full Text] [Related]
39. [Basic immunology and current therapeutic concepts in ocular allergy]. Gehlsen U; Cursiefen C; Steven P Klin Monbl Augenheilkd; 2014 May; 231(5):490-5. PubMed ID: 24799167 [TBL] [Abstract][Full Text] [Related]
40. Urban eye allergy syndrome: a new clinical entity? Leonardi A; Lanier B Curr Med Res Opin; 2008 Aug; 24(8):2295-302. PubMed ID: 18593516 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]